Article metrics

Original research
Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer

 

Online download statistics by month:

Online download statistics by month: June 2021 to May 2024

AbstractFullPdf
Jun 2021408409151
Jul 202129429451
Aug 202114714735
Sep 202111411433
Oct 202110410466
Nov 202112712750
Dec 2021898917
Jan 2022808531
Feb 2022656520
Mar 2022767725
Apr 2022758425
May 2022768235
Jun 2022686917
Jul 2022606017
Aug 2022595923
Sep 2022898930
Oct 2022899339
Nov 2022757526
Dec 2022454514
Jan 2023616120
Feb 2023777922
Mar 2023868736
Apr 2023888936
May 2023727329
Jun 2023969725
Jul 2023646521
Aug 2023818217
Sep 2023626219
Oct 202310410526
Nov 2023989924
Dec 2023787932
Jan 2024495225
Feb 2024767634
Mar 2024969844
Apr 20249610142
May 2024717330
Total349535451187